مقایسه اثربخشی درمان مبتنی بر پذیرش و تعهد و واقعیت درمانی بر تبعیت از درمان در زنان مبتلا به مولتیپل اسکلروزیس

الموضوعات :

مریم باقری ¹ , فرح لطفی کاشانی ² , محمد اسماعیل ابراهیمی ³

1 - دانشجوی دکتری، گروه روانشناسی سلامت، واحد رودهن، دانشگاه آزاد اسلامی، رودهن [e-mail]
2 - (نویسنده مسئول)، دانشیار گروه روانشناسی، دانشکده علوم پزشکی، دانشگاه آزاد اسلامی، تهران، ایران [e-mail], tell: 02122006660
3 - استادیار، گروه روانشناسی، واحد همدان، دانشگاه آزاد اسلامی، همدان، ایران [e-mail]

تاريخ الإرسال : 30 الخميس , ربيع الأول, 1446 تاريخ التأكيد : 19 الخميس , جمادى الأولى, 1446 تاريخ الإصدار : 20 السبت , جمادى الثانية, 1446

الکلمات المفتاحية: پذیرش و تعهد, تبعیت از درمان, مولتیپل اسکلروزیس, واقعیت درمانی,

ملخص المقالة :

چکیده مقدمه: آموزش در زمینه بیماری در افراد مبتلا به بیماری مزمن یک مسئله اساسی و مهم در دستیابی به توانمندسازی و تبعیت مطلوب بیمار است، لذا این پژوهش با هدف، مقایسه اثربخشی درمان مبتنی بر پذیرش و تعهد و واقعیت درمانی بر تبعیت از درمان در زنان مبتلا به مولتیپل اسکلروزیس انجام شد. روش پژوهش:‌ روش پژوهش به صورت نیمه آزمایشی با طرح پیش آزمون- پس آزمون و پیگیری 2 ماهه با گروه کنترل بود. جامعه پژوهش شامل جامعه پژوهش شامل کلیه زنان متأهل مبتلا به مولتیپل اسکلروزیس در شهر همدان در سال 1402 بودند. از این تعداد، 3 گروه 15 نفره با روش نمونه‌گیری در دسترس انتخاب و به صورت تصادفی به گروه‌های آزمایش و گروه کنترل تقسیم شدند و به پرسشنامه تبعیت از درمان بیماری های مزمن مدانلو در سه نوبت پیش- پس¬آزمون و پیگیری پاسخ دادند. آزمودنی‌های گروه آزمایش تحت درمان با رویکرد درمان مبتنی بر پذیرش و تعهد و واقعیت درمانی، طی ۸ جلسه، به صورت هفته‌ای ۱ جلسه 60 دقیقه¬ای به صورت گروهی قرار گرفتند ولی به گروه کنترل آموزشی داده نشد. داده‌ها با نرم‌افزار SPSS و با استفاده از آزمون ت تحلیل واريانس مختلط و سطح معنی‌دار 05/0< p تجزیه ‌و تحلیل آماری شدند. یافته ها: نتایج نشان داد، بین میانگین نمرات پيش آزمون، پس آزمون و پيگيري تبعیت از درمان در سه گروه تفاوت معنادار وجود دارد؛ و برای عامل بین گروهی مقدار F محاسبه شده در سطح کوچکتر از 05/0 معنادار نیست (125/0=Eta , 05/0<, P 990/2= F ) در نتیجه بین میانگین کلی تبعیت از درمان در سه گروه آزمایش و گواه تفاوت معنادار وجود ندارد نتیجه‌گیری: با توجه به نتایج این پژوهش می‌توان گفت، درمان مبتنی بر پذیرش و تعهد و درمان مبتنی بر واقعیت درمانی منجر به تبعیت از درمان در زنان می¬شوند.

highlights:

© 2020 The Author(s). This work is published by family and health as an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by-nc/4.0/). Non-commercial uses of the work are permitted, provided the original work is properly cited.

المصادر:

1. Walton C, King R, Rechtman L, Kaye W, Leray E, Marrie RA, Robertson N, La Rocca N, Uitdehaag B, van der Mei I, Wallin M, Helme A, Angood Napier C, Rijke N, Baneke P. Rising prevalence of multiple sclerosis worldwide: Insights from the Atlas of MS, third edition. Mult Scler. 2020 Dec; 26(14):1816-1821. doi: 10.1177/1352458520970841. Epub 2020 Nov 11. PMID: 33174475; PMCID: PMC7720355.
2. Yang JH, Rempe T, Whitmire N, Dunn-Pirio A, Graves JS. Therapeutic Advances in Multiple Sclerosis. Front Neurol. 2022 Jun 3;13:824926. doi: 10.3389/fneur.2022.824926. PMID: 35720070; PMCID: PMC9205455.
3. Kuhlmann T, Moccia M, Coetzee T, Cohen JA, Correale J, Graves J, Marrie RA, Montalban X, Yong VW, Thompson AJ, Reich DS; International Advisory Committee on Clinical Trials in Multiple Sclerosis. Multiple sclerosis progression: time for a new mechanism-driven framework. Lancet Neurol. 2023 Jan;22(1):78-88. doi: 10.1016/S1474-4422(22)00289-7. Epub 2022 Nov 18. PMID: 36410373; PMCID: PMC10463558.
4. Aghili M, Al Rasool T, Asghari A. The Effectiveness of Self-care Therapy on Psychic Restlessness and Tolerance of Emotional Distress in Women with Multiple Sclerosis. Family and Health. 2023; 12(4): 152-162. https://journal.astara.ir/article_703848.html?lang=en.
5. Jakimovski D, Bittner S, Zivadinov R, Morrow SA, Benedict RH, Zipp F, Weinstock-Guttman B. Multiple sclerosis. Lancet. 2024 Jan 13;403(10422):183-202. doi: 10.1016/S0140-6736(23)01473-3. Epub 2023 Nov 7. PMID: 37949093.
6. Haki M, Al-Biati HA, Al-Tameemi ZS, Ali IS, Al-Hussaniy HA. Review of multiple sclerosis: Epidemiology, etiology, pathophysiology, and treatment. Medicine (Baltimore). 2024 Feb 23;103(8):e37297. doi: 10.1097/MD.0000000000037297. PMID: 38394496; PMCID: PMC10883637.
7. Yamout B, Al-Jumah M, Sahraian MA, Almalik Y, Khaburi JA, Shalaby N, Aljarallah S, Bohlega S, Dahdaleh M, Almahdawi A, Khoury SJ, Koussa S, Slassi E, Daoudi S, Aref H, Mrabet S, Zeineddine M, Zakaria M, Inshasi J, Gouider R, Alroughani R. Consensus recommendations for diagnosis and treatment of Multiple Sclerosis: 2023 revision of the MENACTRIMS guidelines. Mult Scler Relat Disord. 2024 Mar;83:105435. doi: 10.1016/j.msard.2024.105435. Epub 2024 Jan 7. PMID: 38245998.
8. Wang Y, Wang J, Feng J. Multiple sclerosis and pregnancy: Pathogenesis, influencing factors, and treatment options. Autoimmun Rev. 2023 Nov;22(11):103449. doi: 10.1016/j.autrev.2023.103449. Epub 2023 Sep 21. PMID: 37741528.
9. Selmaj K, Cree BAC, Barnett M, Thompson A, Hartung HP. Multiple sclerosis: time for early treatment with high-efficacy drugs. J Neurol. 2024 Jan;271(1):105-115. doi: 10.1007/s00415-023-11969-8. Epub 2023 Oct 18. PMID: 37851189; PMCID: PMC10769939.
10. Castillo Villagrán D, Yeh EA. Pediatric Multiple Sclerosis: Changing the Trajectory of Progression. Curr Neurol Neurosci Rep. 2023 Nov;23(11):657-669. doi: 10.1007/s11910-023-01300-3. Epub 2023 Oct 4. PMID: 37792206.
11. Tavakoli Saleh SH, Esmail Ebrahimi M. Effectivenes of Acceptance- Commitment Therapy on the Resillience and Psycological Well-being of Female Patients with Multiple Sclerosis in Hamadan, Iran. Avicenna J Clin Med. 2021; 28(2): 126-133. doi: 10.52547/ ajcm.28.2.126.
12. Yoysefikia M, Khoshkonesh A, Falahzadeh H. The Effectiveness of Reality Therapy to Decrease the Marital Conflict and Despair in Women with Multiple Sclerosis. Armaghanj 2018; 23 (3): 364-377. URL: http://armaghanj.yums.ac.ir/article-1-1569-fa.html.
13. Woo MS, Engler JB, Friese MA. The neuropathobiology of multiple sclerosis. Nat Rev Neurosci. 2024 Jul;25(7):493-513. doi: 10.1038/s41583-024-00823-z. Epub 2024 May 24. PMID: 38789516.
14. Freedman MS, Gnanapavan S, Booth RA, Calabresi PA, Khalil M, Kuhle J, Lycke J, Olsson T; Consortium of Multiple Sclerosis Centers. Guidance for use of neurofilament light chain as a cerebrospinal fluid and blood biomarker in multiple sclerosis management. EBioMedicine. 2024 Mar;101:104970. doi: 10.1016/j.ebiom.2024.104970. Epub 2024 Feb 13. PMID: 38354532; PMCID: PMC10875256.
15. Maltby VE, Scott RJ, Giovannoni G, Hawkes CH, Levy M, Yeh EA, Lechner-Scott J. Where does multiple sclerosis come from? Mult Scler Relat Disord. 2024 May;85:105575. doi: 10.1016/j.msard.2024.105575. Epub 2024 Mar 23. PMID: 38574723.
16. Chataway J, Williams T, Li V, Marrie RA, Ontaneda D, Fox RJ. Clinical trials for progressive multiple sclerosis: progress, new lessons learned, and remaining challenges. Lancet Neurol. 2024 Mar;23(3):277-301. doi: 10.1016/S1474-4422(24)00027-9. PMID: 38365380.
17. Gill S, Agarwal M. Multiple Sclerosis Part 1: Essentials and the McDonald Criteria. Magn Reson Imaging Clin N Am. 2024 May;32(2):207-220. doi: 10.1016/j.mric.2023.11.002. Epub 2023 Dec 9. PMID: 38555137.
18. Mishra S, Bapuraj J, Srinivasan A. Multiple Sclerosis Part 2: Advanced Imaging and Emerging Techniques. Magn Reson Imaging Clin N Am. 2024 May;32(2):221-231. doi: 10.1016/j.mric.2024.01.002. Epub 2024 Feb 9. PMID: 38555138.
19. Carlson AK, Fox RJ. Pathophysiology, Diagnosis, Treatment and Emerging Neurotherapeutic Targets for Progressive Multiple Sclerosis: The Age of PIRA. Neurol Clin. 2024 Feb;42(1):39-54. doi: 10.1016/j.ncl.2023.07.002. Epub 2023 Aug 21. PMID: 37980122.
20. Alvarez E, Longbrake EE, Rammohan KW, Stankiewicz J, Hersh CM. Secondary hypogammaglobulinemia in patients with multiple sclerosis on anti-CD20 therapy: Pathogenesis, risk of infection, and disease management. Mult Scler Relat Disord. 2023 Nov;79:105009. doi: 10.1016/j.msard.2023.105009. Epub 2023 Sep 15. PMID: 37783194.
21. Bizri M, Koleilat R, Akiki N, Dergham R, Mihailescu AM, Bou-Fakhredin R, Musallam KM, Taher AT. Quality of life, mood disorders, and cognitive impairment in adults with β-thalassemia. Blood Rev. 2024 May;65:101181. doi: 10.1016/j.blre.2024.101181. Epub 2024 Feb 8. PMID: 38341336.
22. Wolf F, Nielsen J, Saliger J, Hennecken E, Kröber P, Eschweiler M, Folkerts AK, Karbe H, Zimmer P. Multimodal agility-based exercise training (MAT) versus strength and endurance training (SET) to improve multiple sclerosis-related fatigue and fatigability during inpatient rehabilitation: a randomized controlled pilot and feasibility study [ReFEx]. BMC Neurol. 2023 Oct 28;23(1):388. doi: 10.1186/s12883-023-03436-8. PMID: 37898772; PMCID: PMC10612282.
23. Hancock LM, Rao SM, Galioto R. Neuropsychological Manifestations of Multiple Sclerosis. Neurol Clin. 2024 Nov;42(4):835-847. doi: 10.1016/j.ncl.2024.05.010. Epub 2024 Jun 14. PMID: 39343478.
24. Van der Hoek LH, Rosenmöller BRAM, van de Rijt LJM, de Vries R, Aarab G, Lobbezoo F. Factors associated with treatment adherence to mandibular advancement devices: a scoping review. Sleep Breath. 2023 Dec;27(6):2527-2544. doi: 10.1007/s11325-023-02862-9. Epub 2023 Jun 29. PMID: 37386300; PMCID: PMC10656313.
25. Bani Hashemi, S., Hatami, M., Hasani, J., sahebi, A. Comparing Effectiveness of the Cognitive-behavioral Therapy, Reality Therapy, and Acceptance and Commitment Therapy on Quality of Life, General Health, and Coping Strategies of Chronic Patient’s Caregivers. Journal of Clinical Psychology, 2020; 12(1): 63-76. doi: 10.22075/jcp.2020.18992.1757.
26. Gulma K. Enhancing public health programs with performance-based memorandum of understanding. J Public Health Policy. 2023 Dec;44(4):634-642. doi: 10.1057/s41271-023-00446-1. Epub 2023 Oct 27. PMID: 37891354.
27. Saadat S, Kalantari M, Kajbaf M B, Hosseininezhad M. A comparative study of health promoting behaviors in healthy individuals and patients with multiple sclerosis: An analytical study. Journal of Hayat 2019; 25 (2): 138-150. URL: http://hayat.tums.ac.ir/article-1-2944-fa.html.
28. Alzahrani AM, Hakami A, AlHadi A, Al-Maflehi N, Aljawadi MH, Alotaibi RM, Alzahrani MM, Alammari SA, Batais MA, Almigbal TH. The effectiveness of mindfulness training in improving medical students' stress, depression, and anxiety. PLoS One. 2023 Oct 31;18(10):e0293539. doi: 10.1371/journal.pone.0293539. PMID: 37906599; PMCID: PMC10617730.
29. Sanabria-Mazo JP, Giné-Vázquez I, Cristobal-Narváez P, Suso-Ribera C, García-Palacios A, McCracken LM, Hayes SC, Hofmann SG, Ciarrochi J, Luciano JV. Relationship between outcomes and processes in patients with chronic low back pain plus depressive symptoms: idiographic analyses within a randomized controlled trial. Psychother Res. 2024 Jul 30:1-16. doi: 10.1080/10503307.2024.2382429. Epub ahead of print. PMID: 39079014.
30. Jafskesh Moghadam A, Shahabizadeh F, Bahrainian A. Comparative Effectiveness of Mindfulness-based Psychotherapy versus Acceptance or Commitment Therapy on Stress Level in Dialysis Patients. J Adv Med Biomed Res 2016; 24 (107): 84-93. URL: http://journal.zums.ac.ir/article-1-3775-fa.html.
31. Zhang Y, Ding Y, Chen X, Li Y, Li J, Hu X. Effectiveness of acceptance and commitment therapy on psychological flexibility, fatigue, sleep disturbance, and quality of life of patients with cancer: A meta-analysis of randomized controlled trials. Worldviews Evid Based Nurs. 2023 Dec;20(6):582-592. doi: 10.1111/wvn.12652. Epub 2023 May 16. PMID: 37194163.
32. Levin ME, Krafft J, Twohig MP. An Overview of Research on Acceptance and Commitment Therapy. Psychiatr Clin North Am. 2024 Jun;47(2):419-431. doi: 10.1016/j.psc.2024.02.007. Epub 2024 Mar 21. PMID: 38724128.
33. Williams AJ, Botanov Y, Giovanetti AK, Perko VL, Sutherland CL, Youngren W, Sakaluk JK. A Metascientific Review of the Evidential Value of Acceptance and Commitment Therapy for Depression. Behav Ther. 2023 Nov;54(6):989-1005. doi: 10.1016/j.beth.2022.06.004. Epub 2022 Jun 26. PMID: 37863589.
34. Liu YE, Lv J, Sun FZ, Liang JJ, Zhang YY, Chen J, Jiang WJ. Effectiveness of group acceptance and commitment therapy in treating depression for acute stroke patients. Brain Behav. 2023 Dec;13(12):e3260. doi: 10.1002/brb3.3260. Epub 2023 Nov 8. PMID: 37938871; PMCID: PMC10726803.
35. Morris EMJ, Johns LC, Gaudiano BA. Acceptance and commitment therapy for psychosis: Current status, lingering questions and future directions. Psychol Psychother. 2024 Mar; 97(1): 41-58. doi: 10.1111/papt.12479. Epub 2023 Jun 26. PMID: 37357973.
36. Twohig MP, Seydavi M, Capel LK, Levin ME, Akbari M. Scoping Review of Acceptance and Commitment Therapy for Obsessive-Compulsive Disorder in Iran. J Cogn Psychother. 2024 Jul 11; 38(3): 211-226. doi: 10.1891/JCP-2023-0009. PMID: 38991742.
37. Kashif M, Albalwi AA, Zulfiqar A, Bashir K, Alharbi AA, Zaidi S. Effects of virtual reality versus motor imagery versus routine physical therapy in patients with Parkinson's disease: a randomized controlled trial. BMC Geriatr. 2024 Mar 5;24(1):229. doi: 10.1186/s12877-024-04845-1. PMID: 38443801; PMCID: PMC10916168.
38. Nègre F, Lemercier-Dugarin M, Kahn-Lewin C, Gomet R, Zerdazi EM, Zerhouni O, Romo L. Virtual reality efficiency as exposure therapy for alcohol use: A systematic literature review. Drug Alcohol Depend. 2023 Dec 1;253:111027. doi: 10.1016/j.drugalcdep.2023.111027. Epub 2023 Nov 15. PMID: 38006671.
39. Lattré T, Decramer A, Vanhaecke J, Van der Linden D, Goubau J. Immersive virtual reality in orthopedic hand therapy. Hand Surg Rehabil. 2024 Sep;43(4):101750. doi: 10.1016/j.hansur.2024.101750. Epub 2024 Jul 4. PMID: 38971226.
40. Rodríguez-Almagro D, Achalandabaso-Ochoa A, Ibáñez-Vera AJ, Góngora-Rodríguez J, Rodríguez-Huguet M. Effectiveness of Virtual Reality Therapy on Balance and Gait in the Elderly: A Systematic Review. Healthcare (Basel). 2024 Jan 9;12(2):158. doi: 10.3390/healthcare12020158. PMID: 38255047; PMCID: PMC10815791.
41. Tan YL, Chang VYX, Ang WHD, Ang WW, Lau Y. Virtual reality exposure therapy for social anxiety disorders: a meta-analysis and meta-regression of randomized controlled trials. Anxiety Stress Coping. 2024 Aug 20:1-20. doi: 10.1080/10615806.2024.2392195. Epub ahead of print. PMID: 39161295.
42. Baugher B, Szewczyk N, Liao J. Augmented reality cueing for freezing of gait: Reviewing an emerging therapy. Parkinsonism Relat Disord. 2023 Nov;116:105834. doi: 10.1016/j.parkreldis.2023.105834. Epub 2023 Sep 7. PMID: 37699779.
43. Dimeff LA, Linehan MM. Dialectical behavior therapy for substance abusers. Addict Sci Clin Pract. 2008 Jun;4(2):39-47. doi: 10.1151/ascp084239. PMID: 18497717; PMCID: PMC2797106.
44. Hayes SC, Luoma JB, Bond FW, Masuda A, Lillis J. Acceptance and commitment therapy: model, processes and outcomes. Behav Res Ther. 2006;44(1):1-25. doi: 10.1016/j.brat.2005.06.006. PMID: 16300724.
45. Glasser W, Zunin LM. Reality therapy. Curr Psychiatr Ther. 1972; 12: 58-61. PMID: 5032914.
46. Modanloo M. Development and psychometric tools adherence of treatment in patients with chronic (dissertation). Tehran: Iran University of Medical Sciences; 2013. (Persian)
47. Hokmabadi, M. E., Bigdeli, I., Asghari ebrahimabad, M. J., Asadi, J. Comparing the Effectiveness of Schema Therapy and Acceptance and Commitment Therapy on Personality Type D and Adherence to Treatment in Patients with Coronary Artery Disease. Journal of Clinical Psychology, 2020; 12(1): 25-36. doi: 10.22075/jcp.2020.12459.1217.
48. Sheydayi Aghdam Sh, Shamseddini lory S, Abassi S, Yosefi S, Abdollahi S, Moradi joo M. The effectiveness of treatment based on acceptance and commitment in reducing distress and inefficient attitudes in patients with MS. Journal of Thought & Behavior in Clinical Psychology. 2014; 9(34): 57-66. https://sanad.iau.ir/Journal/jtbcp/Article/1118339.
49. Herman J. Adherence revisited: The patient’s choice. Orthopedic Nursing. 2024; 21(2): 79- 82.
50. Morrison A, Wertheimer A.I. Complication of quantitative overviews of studies of adherence. Drug J, 2014; 38(2): 197-210. http://dx.doi.org/10.1177/009286150403800213.
51. Zhang T, Li X, Zhou X, Zhan L, Wu F, Huang Z, Sun Y, Feng Y, Du Q. Virtual Reality Therapy for the Management of Chronic Spinal Pain: Systematic Review and Meta-Analysis. JMIR Serious Games. 2024 Feb 12; 12:e50089. doi: 10.2196/50089. PMID: 38345832; PMCID: PMC10897798.
52. Landim SF, López R, Caris A, Castro C, Castillo RD, Avello D, Magnani Branco BH, Valdés-Badilla P, Carmine F, Sandoval C, Vásquez E. Effectiveness of Virtual Reality in Occupational Therapy for Post-Stroke Adults: A Systematic Review. J Clin Med. 2024 Aug 7; 13(16): 4615. doi: 10.3390/jcm13164615. PMID: 39200757; PMCID: PMC11354851.
53. Alashram AR. Combined robot-assisted therapy virtual reality for upper limb rehabilitation in stroke survivors: a systematic review of randomized controlled trials. Neurol Sci. 2024 Nov; 45(11): 5141-5155. doi: 10.1007/s10072-024-07628-z. Epub 2024 Jun 5. PMID: 38837113